Imaging methods and blood test to detect the biomarker carcinoembryonic antigen (CEA) both have limited sensitivity and specificity to detect residual tumor burden and hence often fail to identify patients at risk for relapse early (5, 6). This evidence concerns the gene CEACAM5 and neoplasm.